ARTICLE | Company News
Bio-Fluorescent, Immune Network Research Ltd. deal
February 18, 1997 8:00 AM UTC
BFTI reached an agreement in principal to acquire IMM for 9 million shares. BFTI has about 15 million shares outstanding prior to the merger. IMM develops monoclonal antibody-based products and vaccines to treat AIDS and other immune system disorders. ...